Skip to main content

InnoCare Begins ICP-192 Study in US in FGFR-Altered Cancers

NEW YORK – Chinese drug developer InnoCare Pharma on Wednesday said that it has dosed the first patient in the US in a Phase II study of its pan-FGFR inhibitor ICP-192 in FGFR-aberrant cancers.

InnoCare is developing the drug candidate for various solid tumors with FGFR aberrations. It is currently undergoing Phase I/II trials in China and the US. In China, a Phase II trial of the drug in FGFR-altered, advanced cholangiocarcinoma and urothelial cancer has enrolled close to 20 patients, and researchers have seen patients have partial and complete responses to treatment, the company said in a statement.

A year ago, InnoCare partnered with Beijing-based genomic profiling firm Genetron Health, under which Genetron is providing genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development programs.